Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference

Company Overview - Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for patients with renal, metabolic, and cardiovascular diseases [3] - The company utilizes its Compass platform to gain insights into genetic variants associated with diseases and their biological pathways [3] Upcoming Event - Jason Coloma, Ph.D., CEO of Maze Therapeutics, will present a company overview and engage in one-on-one meetings at the 3rd Annual H.C. Wainwright BioConnect Investor Conference on May 20, 2025 [1][2] - The presentation is scheduled for 11 a.m. ET and will be accessible on the company's website, with a replay available for 60 days [2] Pipeline and Programs - Maze Therapeutics is advancing a pipeline led by two wholly owned programs, MZE829 and MZE782, which represent novel precision medicine approaches for patients [3]